Open AccessVilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Author(s) -
Citrome L.
Publication year - 2012
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/j.1742-1241.2011.02885.x
Subject(s) - medicine , number needed to treat , placebo , number needed to harm , discontinuation , major depressive disorder , adverse effect , antidepressant , tolerability , clinical trial , partial agonist , psychiatry , relative risk , confidence interval , mood , agonist , alternative medicine , anxiety , pathology , receptor
To describe the efficacy and safety of vilazodone for the treatment of major depressive disorder (MDD).